CompletedNCT05657691
Xanamem in depression with cognitive difficulties
Researchers studied Xanamem’s effects on depressive and cognitive symptoms, alongside its safety and tolerability.
MedicationAges 18–75Australia + United Kingdom
Understand this study
Who was this study for?
This study was for people with depression. Listed age limits: 18 years to 75 years. Other eligibility criteria applied.
- Listed locations
- Blacktown and 11 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateStarted: November 28, 2022
- Recruitment status
- Completed
- Enrollment listed in the registry
- 167
- Sponsor
- Actinogen Medical
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- Australia, United Kingdom
- Age range
- From 18 Years to 75 Years
- Official registry ID
- NCT05657691
- Official title
Show the full official title
XanaCIDD: A Double-Blind, Randomized, Placebo Controlled, Parallel-Group Trial to Assess the Safety, Tolerability, and Efficacy of Xanamem® in Adults With Major Depressive Disorder and Impaired Cognition
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Blacktown, Australia · Newcastle, Australia · Brisbane, Australia
7 more locations
- Sippy Downs, Australia
- Melbourne, Australia
- Noble Park, Australia
- London, United Kingdom
- Manchester, United Kingdom
- Motherwell, United Kingdom
- Tankersley, United Kingdom
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Actinogen Medical.
Did this study involve medication?
Yes. The study involved medication, including Xanamem™ and Placebo.
Who was this study for?
This study was for people with depression. Listed age limits: 18 years to 75 years. Other eligibility criteria applied.
